Kirkwood, J., Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Sileni, V., Larkin, J., Nyakas, M., Haydon, A., Dutriaux, C., Schachter, J., Robert, C., Mortier, L., Banerjee, H., Haas, T., Tan, M., Lau, M., Schadendorf, D., Long, G. and Mandala, M. 2021. Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s2. DOI:https://doi.org/10.25251/skin.5.supp.2.